Resources | NITAG RESOURCE CENTER

2021 ∙ JCVI, Public Health England

JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021

2021 ∙ Haute Autorité de Santé, Commission Technique des Vaccinations

Modification of the vaccine schedule against SARS-CoV-2 in the new epidemic context

2021 ∙ JCVI

New COVID-19 vaccine advice for adults living with adults who are immunosuppressed

2021 ∙ JCVI

Optimising the COVID-19 vaccination programme for maximum short-term impact

2021 ∙ Haut Conseil de la santé publique

Potential impact of the circulation of SARS-CoV-2 variants on the COVID - 19 strategy - 9 April, 2021

2021 ∙ Haut Conseil de la santé publique

Priority vaccination of the entourage of people immunocompromised against SARS-Cov 2 - 30 April, 2021

2021 ∙ Haute Autorité de Santé

Update of risk factors for severe forms of Covid-19 and recommendations on the strategy for prioritizing populations to be vaccinated

2021 ∙ JCVI

Update to JCVI advice on booster vaccination in adults

2021 ∙ JCVI

Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated JCVI statement, 7 May 2021

2021 ∙ Haute Autorité de Santé, Commission Technique des Vaccinations

Vaccination of people with a history of Covid-19